Natera agreed to acquire Foresight Diagnostics for $275 million plus up to $175 million in earnouts to integrate Foresight’s PhaseED‑seq phased‑variant technology into Natera’s Signatera circulating tumor DNA (ctDNA) MRD assay and to expand into hematologic cancer testing. Natera said the acquisition will improve assay sensitivity and enable broader minimal residual disease applications, particularly in lymphoma and hematologic malignancies. Foresight’s technology—already used in multiple clinical trials and contributing to guideline inclusion for ctDNA MRD in lymphoma—gives Natera an immediate operational foothold in hematology while enhancing its solid‑tumor MRD capabilities. Management highlighted plans to deploy the platform at scale, leveraging Natera’s lab footprint and payer relationships. The deal underscores consolidation in the liquid‑biopsy space as companies race to raise sensitivity, expand indications and secure clinical utility pathways that drive reimbursement.